ARTICLE | Clinical News
Allovectin-7: Began Phase II trial
February 12, 2001 8:00 AM UTC
Vical Inc. (VICL), San Diego, Calif. Product: Allovectin-7 Business: Cancer, Gene/Cell therapy Therapeutic category: Immune stimulation Target: Melanoma cells Description: Gene encoding HLA-B7 mismat...